Considering these associations, these patients would less likely respond to HT but more likely benefit from anti-HER2 therapy as well as dual-kinase inhibitors (such as lapatinib), which target both EGFR and erb-B2 and are promising in HER2- and EGFR-expressing breast carcinomas (20,21). Here, ERBB2 is linked to breast carcinoma.